Elsevier Announces Genomic and Personalized Medicine Conference Supported by The Lancet
Oxford, UK, 13 January 2010 - Elsevier announced today the Genomic and Personalized Medicine Conference in Arlington, VA, USA from May 16-18, 2010, which is, supported by The Lancet and organized in association with the book ‘Genomic and Personalized Medicine’ by Huntington Willard and Geoffrey Ginsburg.
The conference will serve the needs of a wide group of stakeholders - practicing physicians, physician-scientists, industry leaders, policy makers, and other health care professionals and trainees at all levels. The conference will embrace one of the most promising avenues for advances in diagnosis, prevention, and treatment of human disease.
The topics that will be covered have been derived from the comprehensive, two-volume book ‘Genomic and Personalized Medicine’ published in 2009 and will provide in-depth coverage of the field of genomic and personalized medicine, including genomic and other technologies, state-of-the art of genetic and genomic discoveries for individual diseases and practical uses of genome-based information in clinical medicine. Delegates to this event will be offered a 25% reduction on the two-volume book.
Christine Minihane, Senior Acquisitions Editor for the book commented “Elsevier is proud to be the publisher of ‘Genomic and Personalized Medicine’ and the sponsor of this conference. The work of Huntington Willard and Geoff Ginsburg and their colleagues should be commended. They are defining a field which has valuable implications for all areas of health care research and practice. Elsevier is pleased to have the opportunity to support the collaboration which will transform the practice of diagnosis, prevention and treatment of human disease.”
‘Genomic and Personalized Medicine’ is now inviting abstract submissions from the wider audience for poster presentation; however a select number of abstracts may be chosen for oral presentation at the conference. Abstracts should be submitted by February 8, 2010.
More information about this event can be found at www.genomicandpersonalizedmedicine.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+44 1865 843181